Harry Thomasian Jr., serving as the Chief Financial Officer for Precigen, Inc. (NASDAQ:PGEN), has completed the disposal of 200,000 shares of the company's common stock. The total value of these transactions amounts to approximately $1,113,142. The sales were carried out between June 29 and July 1, 2026, and were executed in accordance with a 10b5-1 trading plan previously established by Mr. Thomasian.
This executive divestment takes place against the backdrop of a substantial 262% appreciation in PGEN shares over the preceding year. Currently, the stock trades at approximately $5.25, a level that sits above the InvestingPro Fair Value assessment, which implies that the potential for further upside from these current price points may be constrained. Analysts, however, continue to hold bullish outlooks, with price targets ranging between $11 and $13.90.
On June 29, Mr. Thomasian sold 28,571 shares at a weighted average price of $5.78 per share. These specific transactions involved multiple executions with prices varying from $5.74 to $5.86. Subsequently, on July 1, an additional 171,429 shares were sold at a weighted average price of $5.53 per share. The prices for these latter transactions ranged from $5.39 to $5.67. Following these transactions, Mr. Thomasian directly holds 354,535 shares of Precigen common stock.
In other recent developments, Precigen Inc. reported its Q1 2026 earnings, surpassing analyst expectations. The company achieved an earnings per share of -$0.02, beating the forecasted -$0.03, and reported revenue of $23.25 million, exceeding the anticipated $20.8 million. Additionally, the U.S. Food and Drug Administration granted orphan drug exclusivity to Precigen’s PAPZIMEOS for the treatment of recurrent respiratory papillomatosis, securing market exclusivity through August 2032. This exclusivity prevents the approval of similar drugs for the same condition during this period. Furthermore, Precigen presented follow-up data from its pivotal trial with PAPZIMEOS at the 2026 annual meeting of the American Society of Clinical Oncology. In response to the clinical trial data, H.C. Wainwright reiterated a Buy rating for Precigen’s stock, maintaining a price target of $14.00. These developments highlight significant progress and recognition for Precigen’s efforts in addressing rare diseases.
The company’s next earnings report is scheduled for August 10, 2026. InvestingPro offers 12 additional exclusive tips and comprehensive financial metrics for PGEN subscribers.